Challenges to healthcare innovation is global in nature. This implies that challenges experienced by the UK health system have global concerns. For example, every country has problems arising from an ageing population, prevalence of multiple long-term conditions, and financial setbacks affecting the sustainability of health care programs. Although the possibility of finding lasting solutions to the myriads of problems plaguing global health systems across the world are usually a country-specific matter, evidence-based studies show that governments need collaboration to deliver results in each local context. But there is also a possibility that remedies to systemic challenges could be available in other countries—a scenario that highlights the window of opportunities from knowledge sharing and technology transfer. The major problem is lack of understanding between innovators, industry regulators, and other stakeholders in the industry. For example, innovators and companies manufacturing quality health products or rendering effective care services in other countries may find it difficult gain approval from UK’s NHS and local markets even though such products and services would benefit UK residents. Thus, the COVID-19 pandemic has uncovered many structural inefficiencies that hinder global health systems from maximizing benefits and opportunities from health innovation in the area of life sciences. The key areas for consideration are: (a) Regulatory setbacks (b) Risks of innovation Sourcing and (c) Procurement difficulties (Arora et al., 2011; Jacobs et al., 2015; Zimmerman et al., 2016).
The issue of exponential innovation
The pace of technology adoption in the healthcare industry is accelerating dramatically. Big players in the innovation process are global investors, business developers and impact investment analysts whose contributions enhance development of global health systems—although their roles are complementary to health administrators, industry stakeholders and health providers. The issue of exponential innovation stems from a combination of falling computation costs, high R&D demands, commoditisation of contract research, and shipping restrictions since the COVID-19 era, including other barriers to entry that significantly lower innovation and competitiveness of health systems. Despite the challenges, private-sector investors are making efforts to democratise and globalize R&D in life sciences. Therefore, the process of integrating innovation in healthcare management is no longer controlled by large, capitalist pharmaceutical companies or government agencies (Larisch et al., 2016).
However, healthcare organizations need a high degree of dynamism to remain relevant in the volatile and very competitive global business environment. To gain competitive advantage and sustain profits, health administrators should also worry and plan about ways to stay ahead of competitors. This objective can be achieved by identifying synergistic forces and leveraging on them to expand network of relationships in life science innovation. Health organizations should also discover and collaborate with more investors (in local or foreign markets) and health care workers in strategic areas of operations (Boushey., 2016).
A global view of innovation in healthcare management—specifically the product development landscape—therefore enables health providers to identify and exploit opportunities in science and technology required to successfully navigate the global healthcare system (Weng et al., 2015).
Regulatory issues
To achieve better regulatory coordination in the health industry, there is need for more efficient sharing of information between industry regulators and health organizations—especially in the areas of product development and procurement. The problem is: there is quite little understanding and collaboration between countries. Further, national regulatory agencies and medical monitoring systems do not have efficient cooperative process and mutually-benefitting agreements that allows synchronization of activities on an international database framework—although standards of EHR systems are similar (Wheeler & Buckley., 2021).
Notwithstanding the setbacks mentioned, there are commendable achievements from industry regulators in many countries. For example, Hyperbolic Holdings GmbH (a Switzerland-based management consulting & strategy advisory firm delivering services on medtech, biotech, nutraceuticals and other health services) bridged the cross-border regulatory gap by manufacturing systems used to conduct one of the most competitive and efficacious COVID rt-PCR tests. Although the pace-setting innovation was CE-marked, it was approved by the U.S. Enterprise User Administration (EUA) at the beginning of 2020. Now, it is available in almost every country in the world—including the whole of Europe although some EU Member Countries initially insisted on conducting their own re-validation tests. Other labs in Asia, Africa, Europe and South America repeatedly carried out similar tests and obtained same results before issuing final approval but focus on this section of the study is the achievement rather than setbacks from global health regulatory bodies. A CE mark refers to a symbol or trademark affixed to many products before they can be sold on the European market (Larisch et al., 2016).
It is pertinent to note, however, that the inefficient approach from regulatory agencies is time-consuming and costly—with greater risks for the populations. For example, some people showing signs of COVID-19 within the testing period were not properly diagnosed for isolation and treatment. The gap created an opportunity for exponential spread of the deadly virus and eventually resulted in loss of lives. The indiscriminate lockdowns in almost every country also had huge economic consequences on individuals, corporate business organizations and global economies that were avoidable with effective guidelines from industry regulators and the right health technologies (Chauhan et al., 2021).
Clinical trials
The COVID-19 pandemic uncovered massive inefficiency that permeated validation process in global clinical trial. It is arguable, too, that the global health crisis increased cost of adapting technology needed for effective diagnosis and manufacturing of efficacious drugs. But generally, the time gap between when medications are developed and tested takes a lot of time, and bigger part of the costs is borne by care users—except in countries practising the Beveridge, Bismarck and NHIS models of care. Thus, high price of health care (or medical inflation) in countries practising the FFS model in relatively- or completely dysfunctional health systems has been a global issue without remedy. No wonder the health sector is a goldmine in less developed and developing countries (Fragidis et al., 2018).
One of the concrete solutions to bridging the chasm between health innovation ecosystems in developed and developing/less-developed countries is a global consensus on the creation of a ‘Bureau of Clinical Standards.’ From a global perspective, this agency will review and adjust protocols observed during clinical trials as well as fast-track approvals in different jurisdictions. Additionally, the global health regulator will enforce strict adherence to quality standards, ethical practice, and traceability of results. Health organizations therefore have a responsibility to tackle acute lack of preparedness within their ecosystems. Hyperbolic Holdings GmbH suggests innovation openness and capacity building as other ways some countries can easily transfer/adapt advanced health technology in a timely manner to help alleviate legal and socio-economic results of the unfolding COVID pandemic (Mele et al., 2021).

Leave a Reply